Evidence map›Paper›PMID 35793922›Full record

ArticleBMJ open2022

Deriving and validating a risk prediction model for long COVID-19: protocol for an observational cohort study using linked Scottish data.

Luke Daines, Rachel H Mulholland, Eleftheria Vasileiou, Vicky Hammersley, David Weatherill, Srinivasa Vittal Katikireddi, Steven Kerr, Emily Moore, Elisa Pesenti, Jennifer K Quint and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Luke Daines *Usher Institute, The University of Edinburgh, Edinburgh, UK luke.daines@ed.ac.uk.ORCID 0000-0003-0564-4000
Rachel H Mulholland *Usher Institute, The University of Edinburgh, Edinburgh, UK.
Eleftheria VasileiouUsher Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-6850-7578
Vicky HammersleyUsher Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-9854-3868
David WeatherillUsher Institute, The University of Edinburgh, Edinburgh, UK.
Srinivasa Vittal KatikireddiMRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow, UK.ORCID 0000-0001-6593-9092
Steven KerrUsher Institute, The University of Edinburgh, Edinburgh, UK.
Emily MoorePublic Health Scotland, Glasgow and Edinburgh, UK.
Elisa PesentiInstitute of Cell Biology, University of Edinburgh, Edinburgh, UK.
Jennifer K QuintFaculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-0149-4869
Syed Ahmar ShahUsher Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-5672-0443
Ting ShiUsher Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-4101-4535
Colin R SimpsonUsher Institute, The University of Edinburgh, Edinburgh, UK.
Chris RobertsonPublic Health Scotland, Glasgow and Edinburgh, UK.
Aziz SheikhUsher Institute, The University of Edinburgh, Edinburgh, UK.
University of Edinburgh · GBImperial College London · GBMRC/CSO Social and Public Health Sciences Unit · GBPublic Health Scotland · GBUniversity of Strathclyde · GBVictoria University of Wellington · NZ

Funding

Chief Scientist Office COV/LTE/20/15Chief Scientist Office SCAF/15/02Medical Research Council MC_PC_19004Medical Research Council MC_PC_19075Medical Research Council MC_UU_00022/2
6 · The paper itself

Abstract

introductionCOVID-19 is commonly experienced as an acute illness, yet some people continue to have symptoms that persist for weeks, or months (commonly referred to as 'long-COVID'). It remains unclear which patients are at highest risk of developing long-COVID. In this protocol, we describe plans to develop a prediction model to identify individuals at risk of developing long-COVID. METHODS AND ANALYSIS: We will use the national Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, a population-level linked dataset of routine electronic healthcare data from 5.4 million individuals in Scotland. We will identify potential indicators for long-COVID by identifying patterns in primary care data linked to information from out-of-hours general practitioner encounters, accident and emergency visits, hospital admissions, outpatient visits, medication prescribing/dispensing and mortality. We will investigate the potential indicators of long-COVID by performing a matched analysis between those with a positive reverse transcriptase PCR (RT-PCR) test for SARS-CoV-2 infection and two control groups: (1) individuals with at least one negative RT-PCR test and never tested positive; (2) the general population (everyone who did not test positive) of Scotland. Cluster analysis will then be used to determine the final definition of the outcome measure for long-COVID. We will then derive, internally and externally validate a prediction model to identify the epidemiological risk factors associated with long-COVID. ETHICS AND DISSEMINATION: The EAVE II study has obtained approvals from the Research Ethics Committee (reference: 12/SS/0201), and the Public Benefit and Privacy Panel for Health and Social Care (reference: 1920-0279). Study findings will be published in peer-reviewed journals and presented at conferences. Understanding the predictors for long-COVID and identifying the patient groups at greatest risk of persisting symptoms will inform future treatments and preventative strategies for long-COVID.

Indexed as

COVID-19Cohort StudiesHospitalizationHumansObservational Studies as TopicPost-Acute COVID-19 SyndromeSARS-CoV-2COVID-19protocols & guidelinespublic health

Identifiers

PMID35793922
PMCPMC9260199
OpenAlexW4284889190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.